Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery due to its larger size and strong negative charge [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their application from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways to Small Nucleic Acid Drug Development - The report outlines the dual pathways of ASO and siRNA, highlighting their distinct mechanisms and therapeutic applications [12][30] Mechanistic Differences: ASO vs. siRNA - ASO employs RNase H-mediated degradation and splicing regulation to inhibit protein expression, while siRNA utilizes the RISC mechanism for mRNA degradation [20][26] Chemical Modifications and Stability - The report details the evolution of chemical modifications across four generations, enhancing the stability and specificity of ASO and siRNA [32][36] Delivery Breakthroughs - The challenges of delivering small nucleic acids across cellular barriers are discussed, emphasizing the need for effective delivery systems [40][44] Safety Optimization - Innovations in toxicity management for ASO and siRNA are crucial for supporting long-term use and chronic disease management [62][64] Commercialization and Boundary Expansion - The report emphasizes the transition from liver-targeted therapies to exploring delivery strategies for other tissues, indicating a strategic shift in the industry [60][61]

Investment Rating - The report indicates a positive investment outlook for the nucleic acid drug industry, anticipating it to become the third major category of drugs, driven by technological innovation and increased capital investment [5]. Core Insights - Nucleic acid drugs are emerging as a new therapeutic approach with high efficiency and low toxicity, particularly in rare diseases, and are expanding into common diseases. The global market for nucleic acid drugs is rapidly growing, supported by expanded indications, policy backing, and research collaborations [5]. - The nucleic acid drug market size grew from 18.816 billion RMB in 2019 to 155.828 billion RMB in 2023, with a compound annual growth rate (CAGR) of 69.64%. However, it is expected to decline to 117.545 billion RMB by 2028, with a negative CAGR of -3.82% [10]. - The industry is witnessing a shift from rare diseases to chronic diseases and tumors, with significant advancements in technology and delivery systems, including AI-assisted design and liver-targeted delivery [34][36][38]. Market Background - Nucleic acid drugs are defined as drugs that utilize nucleic acids to intervene in disease by regulating gene expression. They have shown potential in treating metabolic diseases, genetic disorders, and cancers [6]. - The exploration of nucleic acid drugs began in 1978, with the first commercial product, Vitravene, launched in 1998. The market has since evolved, with significant developments in RNA therapies [7][8]. Market Status - The nucleic acid drug market is primarily focused on rare diseases but is gradually expanding to common diseases. The demand for treatment is urgent due to the high prevalence of rare diseases, with over 7,000 known globally [15]. - Capital investment in the nucleic acid sector has increased, with 23 financing events reported in 2024, totaling nearly 3 billion RMB. This funding supports the development of innovative drug delivery systems and clinical trials [12]. Market Competition - The competitive landscape features a tiered structure, with leading companies such as Saint No Biopharma and Hegia Biopharma in the first tier, followed by companies like Rebio and Haobo Pharmaceutical in the second tier [19][20]. - The report highlights ten recommended brands in the nucleic acid drug space, including Rebio, Watson Biopharma, and Saint No Biopharma, each with unique strengths and challenges in their product pipelines [22][23][24]. Development Trends - Technological breakthroughs in liver-targeted delivery and AI design are driving innovation in the nucleic acid drug industry, with expectations that over 50% of the pipeline will utilize these advancements by 2030 [34]. - The commercialization of nucleic acid drugs is accelerating through licensing agreements and healthcare payment reforms, enhancing drug accessibility and market growth [35]. - The industry is expanding its focus from rare diseases to chronic diseases and tumors, with significant research and clinical trials underway for conditions such as hypertension and Alzheimer's disease [38].

Investment Rating - The industry investment rating is "Strong Outperform" and is maintained [1] Core Insights - siRNA drugs have significant mechanism advantages, with delivery as the core technology. Compared to traditional small molecules and biologics, siRNA drugs can precisely silence pathogenic proteins, degrade effectively, and have a long duration of action, making them a popular direction for new drug development. The core technology focuses on modification and delivery, with liver-external delivery being the current breakthrough focus [2][12] - Overseas giants are entering a harvest period, awaiting proof of concept (POC) for liver-external delivery. Alnylam's GalNAc liver-internal delivery has become the "standard answer" due to its high delivery efficiency and specificity. Other companies like Arrowhead and Dicerna are advancing in clinical stages or commercialization for cardiovascular targets, while liver-external organ targets are still in early development [3][41] - Domestic siRNA drug development is flourishing, with various directions from startups and major pharmaceutical companies. Domestic firms are becoming significant players in the global siRNA arena, with strong business development (BD) willingness from multinational corporations (MNCs) in the liver delivery space. New directions include dual-target and liver-external delivery, narrowing the gap with overseas competitors and potentially leading the industry [4] Summary by Sections siRNA Drug Mechanism Advantages - siRNA drugs can precisely silence pathogenic proteins and have a long duration of action, making them a hot direction for new drug development. The mechanism relies on the RISC complex to degrade target mRNA, with a typical structure of double-stranded RNA [10][12] - The delivery system is crucial for siRNA drug development, as siRNA is hydrophilic and requires specific delivery systems to enhance tissue accumulation and cellular penetration [23][24] Overseas Giants Entering Harvest Period - Alnylam is a pioneer in the siRNA industry, having developed the GalNAc delivery system, which has proven effective in human trials. The company has successfully commercialized several products and is expanding its pipeline in cardiovascular, metabolic, and CNS fields [43][53] Domestic siRNA Drug Development - Domestic companies are actively participating in the siRNA market, with collaborations with MNCs and a focus on innovative delivery methods. The investment recommendation includes companies like HengRui Medicine, Beite, and others in the A-share market, as well as several in the Hong Kong market [4]